GLP-1 drugs

Drugs like Ozempic and Wegovy were originally developed and described as obesity treatments for patients with medical need, but they are increasingly marketed and used as lifestyle drugs for customers seeking cosmetic or wellness benefits. Commentators note this reframing raises questions about access for people with genuine medical need, pricing, and how the pharmaceutical industry positions these medicines.

GLP-1 medications such as Ozempic and Wegovy are being discussed as a new approach to weight loss, moving beyond diet and exercise as the standard advice. Johns Hopkins University is among the institutions weighing in on how these drugs work and what their rise means for obesity treatment. The conversation centers on effectiveness, costs, and how widely these drugs will change care.

A new study finds that people who stop taking GLP-1 weight-loss and diabetes drugs, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings suggest the cardiovascular benefits of these medications depend on continued use, raising questions about how patients should manage long-term treatment.

GLP-1 weight-loss drugs such as Ozempic and Wegovy are being linked to changes in sleep health, with researchers examining how significant weight loss affects sleep apnoea and other sleep disorders. The trend is prompting sleep medicine specialists to rethink diagnosis rates, treatment demand and how therapies like CPAP may be used as more patients take these medications.

Doctors are warning that people taking GLP-1 weight-loss and diabetes drugs such as Ozempic may face heightened health risks during the current heat wave. Concerns center on dehydration, as the medications can suppress thirst and appetite, potentially leaving users vulnerable to heat exhaustion and related complications. Patients are being advised to drink water regularly and take precautions in high temperatures as extreme heat persists across many regions.

Young people taking GLP-1 receptor agonists, the class of drugs that includes Ozempic and Wegovy, are showing nutritional deficiencies, according to coverage in medical news outlets. The reports add to ongoing scrutiny of the drugs' safety in children and adolescents, with clinicians urged to monitor patients' nutrient intake while on the medications.

A functional medicine expert is cautioning that high doses of GLP-1 weight-loss and diabetes drugs may affect more than appetite, potentially disrupting other bodily processes beyond food cravings. The warning, reported by Fox News, adds to ongoing debate about the safety and long-term effects of medications such as Ozempic and Wegovy as their use continues to expand.

GLP-1 medications such as Ozempic and Wegovy, originally developed for diabetes and now widely used for weight loss, are showing effects that reach beyond the scale. A report from The Atlantic examines growing evidence and debate that these drugs may also influence mental health, with patients and clinicians reporting changes in mood, appetite, and behavior, even as questions remain about long-term psychological effects.

New Zealand dairy giant Fonterra is moving to serve the nutritional needs of people taking weight-loss medications such as GLP-1 drugs, which reduce appetite and can leave users short of protein and key nutrients. The company is positioning high-protein dairy products to fill that gap, tapping into one of the fastest-growing trends in global food and health.

Public health coverage is drawing together two related topics: the possible mental health effects of GLP-1 weight-loss and diabetes drugs, and the role of exercise for women going through menopause. Listeners are weighing reported mood changes linked to GLP-1 medications against growing evidence that physical activity can ease menopause symptoms such as hot flashes, sleep problems and weight gain.

Supplement brand Smidge has introduced a companion bundle aimed at people taking GLP-1 medications, designed to support digestion and nutrient intake. The products target common side effects of GLP-1 use, such as digestive discomfort and reduced nutrient absorption, as appetite suppression can make balanced nutrition harder. The launch reflects the fast-growing market for products marketed alongside weight-loss drugs like Ozempic and Wegovy.

A new obesity drug has been described as the most powerful yet after trial participants reportedly lost up to 25% of their body weight. The results, reported by Ars Technica, would surpass figures associated with current GLP-1 medications such as Wegovy and Zepbound, intensifying competition among drugmakers in the fast-growing weight-loss treatment market.

Supplement company Smidge has introduced a GLP-1 Companion Bundle aimed at people taking GLP-1 weight-loss medications, combining products intended to support digestive wellness and whole-food nutrition. The announcement was carried on Yahoo Finance. The company positions the bundle as a way to address nutritional gaps and digestive discomfort that can accompany GLP-1 drug use.

A new report finds that 12.4% of teenagers taking GLP-1 weight-loss and diabetes medications are diagnosed with vitamin D deficiency within a year, and few of them receive nutrition counseling to offset the risk. The findings raise concerns about whether young patients on these increasingly prescribed drugs are getting adequate dietary support alongside treatment.